Published in Cancer Cell on July 01, 2004
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev (2007) 4.46
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ (2008) 2.08
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol (2007) 1.92
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem (2011) 1.82
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood (2006) 1.78
A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol (2010) 1.75
Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J (2005) 1.68
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A (2007) 1.63
HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer (2009) 1.54
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc Natl Acad Sci U S A (2008) 1.43
Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix. J Am Chem Soc (2010) 1.42
HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B (2015) 1.40
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol (2006) 1.34
Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets (2006) 1.33
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Enantioselective total synthesis of (+)-gliocladine C: convergent construction of cyclotryptamine-fused polyoxopiperazines and a general approach for preparing epidithiodioxopiperazines from trioxopiperazine precursors. J Am Chem Soc (2011) 1.21
Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J Biol Chem (2008) 1.19
Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun (2005) 1.18
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov (2014) 1.17
Scalable total syntheses of N-linked tryptamine dimers by direct indole-aniline coupling: psychotrimine and kapakahines B and F. J Am Chem Soc (2010) 1.15
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J Am Chem Soc (2009) 1.15
Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J Biol Chem (2008) 1.13
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer (2008) 1.12
A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem (2008) 1.10
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 1.08
Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors. Phytochem Rev (2009) 1.08
Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer (2007) 1.07
Drug discovery from natural products. J Ind Microbiol Biotechnol (2006) 1.07
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res (2010) 1.07
Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. PLoS One (2010) 1.07
TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer (2013) 1.04
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem (2013) 1.03
Transcriptional switches: chemical approaches to gene regulation. J Biol Chem (2010) 1.02
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med (2013) 1.02
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets (2013) 1.01
Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem (2013) 1.01
In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A (2014) 1.01
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther (2008) 1.00
Baicalin increases VEGF expression and angiogenesis by activating the ERR{alpha}/PGC-1{alpha} pathway. Cardiovasc Res (2010) 1.00
The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. Br J Cancer (2011) 0.98
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling. Proc Natl Acad Sci U S A (2013) 0.96
Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells. J Nat Prod (2008) 0.96
HIF1α protein stability is increased by acetylation at lysine 709. J Biol Chem (2012) 0.96
Short Term Hypoxia Synergizes with Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities. J Biol Chem (2016) 0.96
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod (2008) 0.95
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res (2011) 0.94
Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol (2006) 0.93
A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc (2013) 0.92
Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? Front Pharmacol (2013) 0.92
Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids. Chem Sci (2013) 0.92
Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. Mol Cancer (2009) 0.91
The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities. Oncotarget (2010) 0.91
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med (2010) 0.90
Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein interaction. Chembiochem (2014) 0.89
Enantioselective organocatalytic alpha-sulfenylation of substituted diketopiperazines. Tetrahedron Asymmetry (2009) 0.89
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One (2010) 0.89
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity. Immunity (2015) 0.89
Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem (2012) 0.89
Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. Oncol Lett (2013) 0.88
Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules. ACS Chem Biol (2012) 0.88
Small interfering RNA targeting HIF-1α reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol (2011) 0.87
Efficient Organocatalytic alpha-Sulfenylation of Substituted Piperazine-2,5-diones. Tetrahedron Lett (2009) 0.87
Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol (2013) 0.87
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. Invest New Drugs (2010) 0.86
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. Mol Cancer (2014) 0.86
General approach for preparing epidithiodioxopiperazines from trioxopiperazine precursors: enantioselective total syntheses of (+)- and (-)-gliocladine C, (+)-leptosin D, (+)-T988C, (+)-bionectin A, and (+)-gliocladin A. J Am Chem Soc (2013) 0.85
Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells. Oncotarget (2014) 0.85
Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov (2008) 0.85
The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity. J Biol Chem (2009) 0.84
Hypoxia inhibits nephrogenesis through paracrine Vegfa despite the ability to enhance tubulogenesis. Kidney Int (2015) 0.83
Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nat Cell Biol (2015) 0.83
Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis. PLoS One (2014) 0.83
Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol (2015) 0.83
Mini review: protein-protein interactions in transcription: a fertile ground for helix mimetics. Biopolymers (2011) 0.82
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem Biol (2015) 0.82
Transcriptional tools: Small molecules for modulating CBP KIX-dependent transcriptional activators. Biopolymers (2011) 0.82
Targeting Protein-Protein Interactions in the HIF System. ChemMedChem (2016) 0.81
Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia? Curr Oncol (2016) 0.81
Benzochromenones from the marine crinoid Comantheria rotula inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. J Nat Prod (2007) 0.81
Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells. Mol Pharmacol (2015) 0.81
Small-molecule-directed, efficient generation of retinal pigment epithelium from human pluripotent stem cells. Proc Natl Acad Sci U S A (2015) 0.81
Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer (2011) 0.81
A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain. PLoS One (2013) 0.80
From tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancers. Anat Cell Biol (2012) 0.80
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
The consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set for the human and mouse genomes. Genome Res (2009) 14.90
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science (2002) 7.33
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science (2007) 6.70
Aberrant T cell differentiation in the absence of Dicer. J Exp Med (2005) 6.58
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem (2007) 5.36
Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A (2002) 5.07
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet (2006) 4.98
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev (2006) 4.18
Crystal structures of a Formin Homology-2 domain reveal a tethered dimer architecture. Cell (2004) 3.51
The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell (2006) 3.46
Structure and regulation of Src family kinases. Oncogene (2004) 3.44
Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet (2009) 3.33
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A (2002) 3.28
MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep (2003) 3.24
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
Structural basis for the autoinhibition of focal adhesion kinase. Cell (2007) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Crowding delays treatment and lengthens emergency department length of stay, even among high-acuity patients. Ann Emerg Med (2009) 3.07
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol (2010) 2.84
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature (2011) 2.82
A conserved mechanism for Bni1- and mDia1-induced actin assembly and dual regulation of Bni1 by Bud6 and profilin. Mol Biol Cell (2003) 2.77
Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol (2004) 2.65
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis (2010) 2.46
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A (2004) 2.41
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Cyclic di-GMP sensing via the innate immune signaling protein STING. Mol Cell (2012) 2.38
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res (2003) 2.29
SAP couples Fyn to SLAM immune receptors. Nat Cell Biol (2003) 2.27
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev (2002) 2.26
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol (2003) 2.26
Structure of the autoinhibitory switch in formin mDia1. Structure (2006) 2.26
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol (2010) 2.23
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol (2003) 2.23
p21 transcription is regulated by differential localization of histone H2A.Z. Genes Dev (2007) 2.21
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev (2011) 2.00
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A (2002) 1.99
Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96
Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J Am Chem Soc (2009) 1.92
A survey of New Yorkers after the Sept. 11, 2001, terrorist attacks. Am J Psychiatry (2003) 1.90
DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA (2011) 1.85
E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol (2004) 1.85
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
The use of complementary and alternative medicine among california adults with and without cancer. Evid Based Complement Alternat Med (2005) 1.82
Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol Cell (2012) 1.79
Surveillance cultures to monitor quality of gastrointestinal endoscope reprocessing. Am J Gastroenterol (2003) 1.74
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood (2005) 1.73
Spatial and temporal regulation of focal adhesion kinase activity in living cells. Mol Cell Biol (2007) 1.72
The p400 E1A-associated protein is a novel component of the p53 --> p21 senescence pathway. Genes Dev (2005) 1.70
Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res (2008) 1.65
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem (2005) 1.57
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med (2013) 1.56
Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell (2003) 1.55
Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis (2011) 1.51
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res (2011) 1.50
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res (2010) 1.48
Small DNA tumor viruses: large contributors to biomedical sciences. Virology (2009) 1.48
Origins of peptide selectivity and phosphoinositide binding revealed by structures of disabled-1 PTB domain complexes. Structure (2003) 1.48
BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell (2011) 1.48
Impaired autoregulation of cerebral blood flow during rewarming from hypothermic cardiopulmonary bypass and its potential association with stroke. Anesth Analg (2009) 1.47
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem (2011) 1.45
Intraabdominal partitioning of the laparoscopic sleeve gastrectomy remnant optimizes the specimen extraction ergonomics and postoperative pain and is an attractive technique in teenage patients. J Laparoendosc Adv Surg Tech A (2014) 1.43
Homeotic transformations of the axial skeleton that accompany a targeted deletion of E2f6. EMBO Rep (2002) 1.43
Caring for returning Veterans: meeting mental health needs. J Clin Psychiatry (2013) 1.39
X chromosome inactivation in the absence of Dicer. Proc Natl Acad Sci U S A (2009) 1.38
The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest Ophthalmol Vis Sci (2011) 1.37
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol (2007) 1.36
Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. Cancer (2011) 1.36
Structure and function of the interacting domains of Spire and Fmn-family formins. Proc Natl Acad Sci U S A (2011) 1.36
FERM domain interaction promotes FAK signaling. Mol Cell Biol (2004) 1.34
Mechanisms of BRCA1 tumor suppression. Cancer Discov (2012) 1.32